Product Details

Lentiviral vectors efficiently deliver genes into diverse cell types, including challenging ones, ensuring long-term transgene expression. They integrate into the host genome in both dividing and post-mitotic cells. With the capacity for larger genetic payloads, lentiviral vectors are nonpathogenic and don't induce inflammation, making them ideal for in vivo and ex vivo gene and cell therapies.

Creative Biogene offers a range of premade control lentiviral particles. Our negative controls are used in target overexpression, shRNA knockdown, and optional inducible expression. They serve as negative controls for lentivirus treatment. The positive transduction controls optimize transduction conditions or determine target cell sensitivity to infection. These ready-to-use lentiviruses facilitate immediate cell transduction upon receipt. If you have any special requirements, please feel free to contact us.

Advantages of Control Lentiviral Particles

• Comprehensive Lentiviral Controls: Inclusive of reporters and benchmarks for comprehensive experimental design. Facilitates precise and reliable control in lentiviral-based studies.
• Stringent Quality Control: Undergoes stringent quality control measures to ensure reliability and reproducibility. Delivered in ready-to-use formats for immediate experimental implementation.
• Customized Lentivirus Production Services: Offers customized lentivirus production services to meet specific research needs. Tailored solutions for personalized experimental requirements.
• Streamlined Optimization of Transduction Parameters: Aids in the streamlined optimization of transduction parameters for enhanced efficiency. Ensures optimal performance in lentiviral transduction experiments.

Control Lentiviral Particles Product List

Application

The control lentiviruses enable the optimization of transduction parameters for new cell targets. Positive reporters calibrate sensitivity to infection. Negative controls benchmark specificity. The principle involves transducing cells with the panel to identify the optimal viral dose and incubation time for high delivery with minimal toxicity. Positive controls also allow rapid testing of expression constructs. The standardized control lentivirus panel provides rigorous benchmarks to establish ideal infection settings and validate expression systems. The potential applications of the following products may align with your current search:

• Transduction Optimization: Identify the most effective transduction conditions for novel cell targets by assessing optimal viral dose, incubation time, and other parameters. Enables precise tuning of lentiviral delivery to achieve maximum transduction efficiency in diverse cell types.
• Sensitivity Calibration: Calibrate sensitivity to infection by utilizing lentiviral particles with positive reporters, allowing for accurate measurement and quantification. Positive reporters facilitate the establishment of reliable infection sensitivity thresholds.
• Baseline Specificity Determination: Utilize lentiviral particles with negative controls to establish baseline specificity, aiding in the differentiation between specific and non-specific effects. Negative controls provide a reference point for evaluating the specificity of lentiviral transduction.
• Parameter Optimization: Optimize various parameters, including viral dose and incubation time, to fine-tune lentiviral transduction settings for consistent and reproducible results. Standardized tools ensure the establishment of ideal infection parameters.
• Standardized Tools for Ideal Infection Settings: Employ standardized lentiviral tools to establish and maintain ideal infection settings across experiments. Consistent use of standardized tools enhances the reliability and reproducibility of lentiviral transduction.
• Infection Setting Establishment: Use lentiviral particles to establish ideal infection settings, contributing to the optimization of experimental conditions. Lentiviral tools play a crucial role in determining and maintaining optimal infection conditions for various research applications.

Case Study

Case Study 1

Temozolomide (TMZ) resistance in glioblastoma (GBM) is linked to heightened LncRNA SOX2OT expression. In this investigation, cells underwent transfection with sh-NC (Negative Control) or sh-SOX2OT lentiviral vectors to suppress SOX2OT expression, as validated by qRT-PCR. For SOX2OT overexpression, cells were transfected with LV-NC or LV-SOX2OT lentiviral vectors. The CCK-8 assay demonstrated that SOX2OT depletion significantly reduced cell viability and chemoresistance, resulting in diminished IC50 values upon TMZ treatment. Conversely, SOX2OT overexpression increased cell viability, yielding elevated IC50 values. The inclusion of Negative Control groups with lentiviral vectors was instrumental in ensuring the robustness of experimental outcomes.

Figure 1. SOX2OT upregulation in GBM cells resulted in TMZ resistance, enhanced cell proliferation, and inhibited apoptosis. CCK-8 assays measured TMZ sensitivity, cell viability, apoptosis rate, and EdU incorporation in sh-SOX2OT or LV-SOX2OT cells treated with TMZ. Results showed significant differences compared with control groups.

Case Study 2

Researchers employed lentiviral vectors to investigate the impact of CXCL5 on glioblastoma (GBM) biological functions. Transcriptome microarray analysis, RT-qPCR, and Western Blot confirmed elevated CXCL5 expression in GBM. Inhibiting CXCL5 demonstrated efficacy in suppressing proliferation and angiogenesis, extending survival rates in xenograft models. Dapsone pretreatment reversed CXCL5's impact on colony and tube formation in GBM cells. High CXCL5 expression correlated with poor outcomes in GBM patients. Overexpression of CXCL5 activated JAK-STAT and NF-κB signaling pathways.

Figure 2. U87 and U251 GBM cells underwent multiple studies to investigate CXCL5's physiological functions, inhibiting endogenous CXCL5 expression through pGFP-shCXCL5 lentivirus infection, with shNT lentivirus as the control. (Mao P, et al., 2023).

Case Study 3

In investigating the mechanism of lncRNA Myocardial Infarction-Associated Transcript (MIAT) in hypoxic-ischemic (HI)-induced neonatal cerebral palsy, researchers utilized a neonatal rat model of HI injury. They observed the downregulation of MIAT and glial cell line-derived neurotrophic factor (GDNF) in HI-induced striatal tissues and Neuro2A cells subjected to oxygen-glucose deprivation (OGD). MIAT overexpression demonstrated neuroprotective effects by reducing apoptosis through the miR-211/GDNF pathway, providing insights into potential therapeutic strategies for neonatal cerebral palsy.

Figure 3. Researchers injected lenti-NC or lenti-MIAT into the cortex of neonatal rats, establishing a neonatal rat model of hypoxic-ischemic (HI) injury three days post-injection, while lenti-NC served as control. (Li E Y, et al., 2019)

FAQ